As per the findings of a recent report by Transparency Market Research (TMR), the global alpha mannosidosis market has only two major players in Cytomedix, Inc. and Zymenex A/S, while the new entrants are challenged by high investment required for the manufacture of mannosidosis in an unguaranteed return of investment scenario. Stringent regulations pertaining to enzyme replacement therapy (ERT) approval is another factor that is discouraging new players, although large number of suppliers are available.
The TMR report evaluates that global alpha mannosidosis market was worth merely US$2.62 mn in 2015, but rising at a robust CAGR of 11.9% during the forecast period of 2016 to 2024, it is estimated to value US$21.75 mn by 2024. The clinical trials conducted by Zymenex A/S and Cytomedix, Inc. in order to develop monotherapy products and combination products with various molecule type is expected to maintain the stronghold of these two leading players in the global market for alpha mannosidosis market in the near future.
This 109 page report gives readers a comprehensive overview of the alpha mannosidosis market. Browse through 19 data tables and 32 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/alpha-mannosidosis-market.html
Enzyme Replacement Therapy Segment Serves Maximum Demand
Treatment-wise, the report segments the global alpha mannosidosis market into bone marrow transplant and enzyme replacement therapy. Among these, enzyme replacement therapy segment is expected to expand at an impressive CAGR of 13.1% during the forecast period US$16.0 mn by 2024, which is a reflection of its high efficacy. Based on indication, the report categorizes the market into type I, type II, and type III. While type I is a mild form delineated by clinical recognition of the disease after age ten years and is characterized by the absence of skeletal abnormalities, type II is a moderate form with clinical recognition before age ten years. Type III is the severe form with obvious progression and leads to early death. Among these, type II indication segment is expected to be worth the maximum at S$12.7 mn by the end of the forecast period, although type III segment is projected for a slightly better growth rate.
On the basis of end user, the report bifurcates the global alpha mannosidosis market into hospitals and specialty clinics. The specialty clinics segment is expected to show considerable growth in the near future, although hospitals will continue to be the primary end-user category. Geographically, the report expects vastly populated Asia Pacific to be the most lucrative region in the near future, although the prevalence of lysosomal storage disorders (LSD) was found equally prevalent in North America and Europe.
Exclusivity of Orphan Drugs Driving Demand
The global alpha mannosidosis market is primarily drive by exclusivity of orphan drugs. This allows pharmaceutical companies to recover costs incurred in development, as during the forecast period, regulatory agencies are not expected to approve a generic equivalent of the drug for the same rare indication. Fee reduction and tax credits is another important factor driving the global alpha mannosidosis market. Orphan drug designation qualifies the orphan drug manufacturer to claim tax credits of up to 50% of research and development costs incurred during the clinical trial phase in the U.S. Some of the other favorable factors for the global alpha mannosidosis market are: increasing investment in rare disease treatment, favorable reimbursement, longer market exclusivity, reduced marketing costs, premium pricing, and faster market access. On the other hand, factors such as high cost of producing an orphan drug, discounted purchase, research challenges such as limitation of disease knowledge, and the lack of awareness among the patients are expected to hinder the market from reaching its true potential.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving alpha mannosidosis market during 2017 – 2024: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2501
According to the author of the report, “Therapies targeting neuropathic lysosomal storage disorder by cross blood brain barrier and therapies that overcome immune response and better tissue selectivity are expected to open new opportunities for the players in this market.”
The information presented in this review is based on a Transparency Market Research report, titled, “Alpha Mannosidosis Market (Treatment – Bone Marrow Transplant (BMT) and Enzyme Replacement Therapy (ERT); Indication – Type I, Type II and Type III; End Users – Hospitals and Specialty Clinics) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 – 2024.”